How to Choose Between Fixed-Duration vs Continuous BTKi Therapy for CLL
December 10th 2024Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health, discussed the decision-making process for selecting between fixed-duration options and continuous Bruton tyrosine kinase inhibitor (BTKi) therapy for patients with chronic lymphocytic leukemia (CLL).
Read More
6-Year Data Support Fixed-Duration Ven-Obi for Untreated CLL
December 10th 2024Long-term data support the safety and efficacy of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL), though questions remain about which patients would benefit most from the regimen.
Read More
Individualized Niraparib Starter Dosing Cuts AE Costs in Ovarian Cancer by 48%
December 9th 2024Implementing an individualized starting dose (ISD) of niraparib (Zejula; GSK) reduced severe hematologic adverse event (AE) management costs by 48% compared with a fixed starting dose (FSD) in US patients with ovarian cancer.
Read More
Higher Dietary Magnesium Intake Linked to Reduced Frailty Risk in Patients With COPD
December 9th 2024Higher dietary magnesium intake is associated with a reduced risk of frailty in patients with chronic obstructive pulmonary disease (COPD), emphasizing its potential role in improving clinical outcomes.
Read More
Spike in Food Recalls Sparks Consumer Concern Amid Foodborne Illness Outbreaks
December 9th 2024Recent surges in FDA and US Department of Agriculture food recalls due to salmonella, Escherichia coli, and listeria outbreaks highlight ongoing food safety challenges and advancements in pathogen detection technology.
Read More
ICYMI: Highlights From ASPC Congress 2024
December 9th 2024The top 5 most-viewed content from this year's American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease (CVD) Prevention included interviews with Robert Kushner, MD, MS, and Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC, as well as coverage on multiple areas of cardiovascular medicine.
Read More
Nanoparticle Delivery Holds Promise for Treatment of PAH
December 8th 2024Aerosolized vascular endothelial growth factor/stromal cell-derived factor-1α (VEGFNP/SDFNP) led to a lower pulmonary arterial pressure and prevented right ventricular hypertrophy after monocrotaline (MCT) injection in rats.
Read More
Receiving ASCT After First CR May Improve Certain Outcomes in AML
December 7th 2024The meta-analysis found indications that autologous stem cell transplantation (ASCT) is associated with higher rates of disease-free survival and relapse-free survival, as well as lower rates of relapse compared with chemotherapy after patients achieved their first complete response (CR).
Read More
Clinical Features Vary Across Myasthenia Gravis Foundation Classes
December 7th 2024Myasthenia Gravis Foundation of America (MGFA) class correlates with activities of daily living and other clinical characteristics on a group level, but individual variability is significant between patients of the same MGFA class.
Read More
New Data Reinforce Iptacopan's Role in Transforming PNH Care With Hemoglobin, QOL Gains
December 6th 2024Promising topline results from a phase 3B study show the efficacy and quality of life (QOL) improvements of iptacopan (Fabhalta) as a twice-daily oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who transitioned from anti-C5 therapies.
Read More
Acoramidis Sustains Benefits in Patients With ATTR-CM in Open-Label Extension Study
December 6th 2024Data presented at the 2024 American Heart Association (AHA) Scientific Sessions showed that continuous treatment with acoramidis (Attruby; BridgeBio Pharma) significantly reduced the risk of all-cause mortality (ACM) and cardiovascular-related hospitalizations (CVH) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
Read More
ICYMI: Highlights From ERS Congress 2024
December 6th 2024Top coverage from the European Respiratory Society (ERS) Congress 2024 spanned various topics, including artificial intelligence–powered robots transforming respiratory care and late-breaking findings on an epilepsy drug showing promise for treating obstructive sleep apnea.
Read More